Protein kinase C modulation of cyclic GMP in rat neonatal pulmonary vascular smooth muscle

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Protein kinase C (PKC) has been implicated in the control of vascular tone and mitogenesis in the adult pulmonary vasculature, but little is known about the role of PKC in the neonatal pulmonary vasculature. In addition, the vasodilator nitric oxide (NO) is important in the transition of the pulmonary circulation from fetal to postnatal life, and it is thought that attenuated production of NO and therefore, cGMP may contribute to the pathophysiology of a variety of forms of neonatal pulmonary vascular disease states. Although evidence exists for an interaction between PKC and NO in the adult pulmonary vasculature, the identification of specific roles for PKC in neonatal pulmonary vascular smooth muscle (NPVSM) has not been determined, and no studies have been done on the modulation of cGMP by PKC in NPVSM. Accordingly, immunoblot analysis revealed the expression of the α, δ, ε, and ι PKC isozymes in NPVSM. Treatment of NPVSM with 10nM 4-β phorbol myristate acetate (PMA), a PKC activator, induced translocation of PKCα, and PKCδ from the soluble to the particulate fraction, while exposure to 10nM endothelin-1 (ET-1), a potent vasoconstrictor and mitogenic substance, caused translocation of PKCδ and PKCι from the soluble to the particulate fraction. Sodium nitroprusside (SNP) significantly increased intracellular cGMP levels, an effect attenuated by PMA but not by ET-1. In addition, pretreatment with the specific PKC isozyme antagonist Go 6983 blocked the effect of PMA on cGMP levels. Collectively, these data demonstrate the expression and activation of multiple PKC isozymes in NPVSM, and indicate that PKC inhibits SNP-stimulated cGMP production in NPVSM. These data also suggest that complex intracellular signaling pathways by specific PKC isozymes may be important in the development of neonatal pulmonary vascular function.

Original languageEnglish (US)
Pages (from-to)79-89
Number of pages11
JournalLung
Volume182
Issue number2
DOIs
StatePublished - May 10 2004

Fingerprint

Cyclic GMP
Vascular Smooth Muscle
Protein Kinase C
Lung
Isoenzymes
Tetradecanoylphorbol Acetate
Nitric Oxide
Nitroprusside
Endothelin-1
Blood Vessels
Pulmonary Circulation
Muscle Proteins
Vasoconstrictor Agents
Vasodilator Agents
Vascular Diseases
Lung Diseases

Keywords

  • Cyclic GMP
  • Endothelin-1
  • Neonatal pulmonary vascular smooth muscle
  • Phorbol myristate acetate
  • Protein kinase C isozymes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Protein kinase C modulation of cyclic GMP in rat neonatal pulmonary vascular smooth muscle. / Johnson, John A; Barman, Scott A.

In: Lung, Vol. 182, No. 2, 10.05.2004, p. 79-89.

Research output: Contribution to journalArticle

@article{8ab7155c90a442048f39db53443140aa,
title = "Protein kinase C modulation of cyclic GMP in rat neonatal pulmonary vascular smooth muscle",
abstract = "Protein kinase C (PKC) has been implicated in the control of vascular tone and mitogenesis in the adult pulmonary vasculature, but little is known about the role of PKC in the neonatal pulmonary vasculature. In addition, the vasodilator nitric oxide (NO) is important in the transition of the pulmonary circulation from fetal to postnatal life, and it is thought that attenuated production of NO and therefore, cGMP may contribute to the pathophysiology of a variety of forms of neonatal pulmonary vascular disease states. Although evidence exists for an interaction between PKC and NO in the adult pulmonary vasculature, the identification of specific roles for PKC in neonatal pulmonary vascular smooth muscle (NPVSM) has not been determined, and no studies have been done on the modulation of cGMP by PKC in NPVSM. Accordingly, immunoblot analysis revealed the expression of the α, δ, ε, and ι PKC isozymes in NPVSM. Treatment of NPVSM with 10nM 4-β phorbol myristate acetate (PMA), a PKC activator, induced translocation of PKCα, and PKCδ from the soluble to the particulate fraction, while exposure to 10nM endothelin-1 (ET-1), a potent vasoconstrictor and mitogenic substance, caused translocation of PKCδ and PKCι from the soluble to the particulate fraction. Sodium nitroprusside (SNP) significantly increased intracellular cGMP levels, an effect attenuated by PMA but not by ET-1. In addition, pretreatment with the specific PKC isozyme antagonist Go 6983 blocked the effect of PMA on cGMP levels. Collectively, these data demonstrate the expression and activation of multiple PKC isozymes in NPVSM, and indicate that PKC inhibits SNP-stimulated cGMP production in NPVSM. These data also suggest that complex intracellular signaling pathways by specific PKC isozymes may be important in the development of neonatal pulmonary vascular function.",
keywords = "Cyclic GMP, Endothelin-1, Neonatal pulmonary vascular smooth muscle, Phorbol myristate acetate, Protein kinase C isozymes",
author = "Johnson, {John A} and Barman, {Scott A}",
year = "2004",
month = "5",
day = "10",
doi = "10.1007/s00408-003-1046-6",
language = "English (US)",
volume = "182",
pages = "79--89",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Protein kinase C modulation of cyclic GMP in rat neonatal pulmonary vascular smooth muscle

AU - Johnson, John A

AU - Barman, Scott A

PY - 2004/5/10

Y1 - 2004/5/10

N2 - Protein kinase C (PKC) has been implicated in the control of vascular tone and mitogenesis in the adult pulmonary vasculature, but little is known about the role of PKC in the neonatal pulmonary vasculature. In addition, the vasodilator nitric oxide (NO) is important in the transition of the pulmonary circulation from fetal to postnatal life, and it is thought that attenuated production of NO and therefore, cGMP may contribute to the pathophysiology of a variety of forms of neonatal pulmonary vascular disease states. Although evidence exists for an interaction between PKC and NO in the adult pulmonary vasculature, the identification of specific roles for PKC in neonatal pulmonary vascular smooth muscle (NPVSM) has not been determined, and no studies have been done on the modulation of cGMP by PKC in NPVSM. Accordingly, immunoblot analysis revealed the expression of the α, δ, ε, and ι PKC isozymes in NPVSM. Treatment of NPVSM with 10nM 4-β phorbol myristate acetate (PMA), a PKC activator, induced translocation of PKCα, and PKCδ from the soluble to the particulate fraction, while exposure to 10nM endothelin-1 (ET-1), a potent vasoconstrictor and mitogenic substance, caused translocation of PKCδ and PKCι from the soluble to the particulate fraction. Sodium nitroprusside (SNP) significantly increased intracellular cGMP levels, an effect attenuated by PMA but not by ET-1. In addition, pretreatment with the specific PKC isozyme antagonist Go 6983 blocked the effect of PMA on cGMP levels. Collectively, these data demonstrate the expression and activation of multiple PKC isozymes in NPVSM, and indicate that PKC inhibits SNP-stimulated cGMP production in NPVSM. These data also suggest that complex intracellular signaling pathways by specific PKC isozymes may be important in the development of neonatal pulmonary vascular function.

AB - Protein kinase C (PKC) has been implicated in the control of vascular tone and mitogenesis in the adult pulmonary vasculature, but little is known about the role of PKC in the neonatal pulmonary vasculature. In addition, the vasodilator nitric oxide (NO) is important in the transition of the pulmonary circulation from fetal to postnatal life, and it is thought that attenuated production of NO and therefore, cGMP may contribute to the pathophysiology of a variety of forms of neonatal pulmonary vascular disease states. Although evidence exists for an interaction between PKC and NO in the adult pulmonary vasculature, the identification of specific roles for PKC in neonatal pulmonary vascular smooth muscle (NPVSM) has not been determined, and no studies have been done on the modulation of cGMP by PKC in NPVSM. Accordingly, immunoblot analysis revealed the expression of the α, δ, ε, and ι PKC isozymes in NPVSM. Treatment of NPVSM with 10nM 4-β phorbol myristate acetate (PMA), a PKC activator, induced translocation of PKCα, and PKCδ from the soluble to the particulate fraction, while exposure to 10nM endothelin-1 (ET-1), a potent vasoconstrictor and mitogenic substance, caused translocation of PKCδ and PKCι from the soluble to the particulate fraction. Sodium nitroprusside (SNP) significantly increased intracellular cGMP levels, an effect attenuated by PMA but not by ET-1. In addition, pretreatment with the specific PKC isozyme antagonist Go 6983 blocked the effect of PMA on cGMP levels. Collectively, these data demonstrate the expression and activation of multiple PKC isozymes in NPVSM, and indicate that PKC inhibits SNP-stimulated cGMP production in NPVSM. These data also suggest that complex intracellular signaling pathways by specific PKC isozymes may be important in the development of neonatal pulmonary vascular function.

KW - Cyclic GMP

KW - Endothelin-1

KW - Neonatal pulmonary vascular smooth muscle

KW - Phorbol myristate acetate

KW - Protein kinase C isozymes

UR - http://www.scopus.com/inward/record.url?scp=2142654340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142654340&partnerID=8YFLogxK

U2 - 10.1007/s00408-003-1046-6

DO - 10.1007/s00408-003-1046-6

M3 - Article

C2 - 15136882

AN - SCOPUS:2142654340

VL - 182

SP - 79

EP - 89

JO - Lung

JF - Lung

SN - 0341-2040

IS - 2

ER -